PerkinElmer Acquires Vanadis Diagnostics, AB

Gains Innovative NIPT Solution in Development to Expand Maternal
Fetal Health Portfolio

a global leader focused on improving the health and safety of
people and the environment, today announced that it has completed the
acquisition of Vanadis
Diagnostics, AB.
Based in Sweden, Vanadis is developing a novel
solution for non-invasive prenatal testing (NIPT) based on digital
analysis of cell-free DNA.

The acquisition is anticipated to build upon PerkinElmer’s maternal
fetal health offerings, which provide customers a full portfolio of
traditional serum screening solutions. The Vanadis platform will enable
PerkinElmer to offer a simplified, cost-effective, high-throughput
approach to NIPT to help facilitate wider access for pregnant women.

Many traditional biochemistry prenatal testing labs have encountered
challenges in successfully implementing NIPT due to the complexity of
the tests. This has led to limited acceptance of the existing NIPT
technology, which has been adopted mainly by genetic laboratories. The
Vanadis offering is based on digital DNA analysis and is designed to
provide automated testing for routine use by high-throughput
biochemistry labs as well as genetic labs.

“While NIPT is becoming increasingly recognized as valuable to many
high-risk expectant parents during the first trimester, test complexity
and pricing issues have limited the ability of many biochemistry labs to
effectively offer this type of prenatal screening,” said Prahlad Singh,
President, Diagnostics, PerkinElmer. “High capital investment, advanced
molecular skills, and complex data handling for lab staff, along with
the difficulty of integrating these systems into the existing screening
infrastructure, have been barriers to more widespread adoption of NIPT.
Vanadis’ simplified NIPT platform, once available, should help overcome
these obstacles, giving labs a wider range of prenatal testing
capabilities and providing important information to physicians and

Adding Vanadis’ capabilities to PerkinElmer’s extensive diagnostics
portfolio is intended to contribute to better health outcomes through
improved detection of fetal chromosomal abnormalities. PerkinElmer’s
diagnostic offerings include: prenatal, neonatal and infectious disease
screening, along with molecular diagnostics solutions, through its wide
range of instruments, reagents and assay platforms, and software. The
Company also provides private cord blood and cord tissue preservation to
families through ViaCord LLC.

“We founded Vanadis with the mission to make NIPT available to all
women, and we developed this technology to fundamentally change the cost
structure and workflow for NIPT,” said Olle Ericsson, CEO, Vanadis
Diagnostics. “We are confident that with its leading position in
prenatal screening, PerkinElmer is best situated to bring this system to
market and address the under-served segment of average-risk pregnancies.”

About PerkinElmer, Inc.
PerkinElmer, Inc. is a global leader
focused on improving the health and safety of people and the
environment. The Company reported revenue of approximately $2.2 billion
in 2014, has approximately 8,000 employees serving customers in more
than 150 countries, and is a component of the S&P 500 Index. Additional
information is available through 1-877-PKI-NYSE, or at

Factors Affecting Future Performance
This press release
contains “forward-looking” statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including, but not limited to,
statements relating to estimates and projections of future earnings per
share, cash flow and revenue growth and other financial results,
developments relating to our customers and end-markets, and plans
concerning business development opportunities and divestitures. Words
such as “believes,” “intends,” “anticipates,” “plans,” “expects,”
“projects,” “forecasts,” “will” and similar expressions, and references
to guidance, are intended to identify forward-looking statements. Such
statements are based on management’s current assumptions and
expectations and no assurances can be given that our assumptions or
expectations will prove to be correct. A number of important risk
factors could cause actual results to differ materially from the results
described, implied or projected in any forward-looking statements. These
factors include, without limitation: (1) markets into which we sell our
products declining or not growing as anticipated; (2) fluctuations in
the global economic and political environments; (3) our failure to
introduce new products in a timely manner; (4) our ability to execute
acquisitions and license technologies, or to successfully integrate
acquired businesses and licensed technologies into our existing business
or to make them profitable, or successfully divest businesses; (5) our
failure to adequately protect our intellectual property; (6) the loss of
any of our licenses or licensed rights; (7) our ability to compete
effectively; (8) fluctuation in our quarterly operating results and our
ability to adjust our operations to address unexpected changes; (9)
significant disruption in third-party package delivery and import/export
services or significant increases in prices for those services; (10)
disruptions in the supply of raw materials and supplies; (11) the
manufacture and sale of products exposing us to product liability
claims; (12) our failure to maintain compliance with applicable
government regulations; (13) regulatory changes; (14) our failure to
comply with healthcare industry regulations; (15) economic, political
and other risks associated with foreign operations; (16) our ability to
retain key personnel; (17) significant disruption in our information
technology systems; (18) our ability to obtain future financing; (19)
restrictions in our credit agreements; (20) our ability to realize the
full value of our intangible assets; (21) significant fluctuations in
our stock price; (22) reduction or elimination of dividends on our
common stock; and (23) other factors which we describe under the caption
“Risk Factors” in our most recent quarterly report on Form 10-Q and in
our other filings with the Securities and Exchange Commission. We
disclaim any intention or obligation to update any forward-looking
statements as a result of developments occurring after the date of this
press release.


Investor Relations:
Tommy J. Thomas, 781-663-5889
Willinsky, 781-663-5728